About NEPHRODITE, INC.
Nephrodite is developing an implantable dialysis platform called Holly™, designed to provide continuous blood filtration for patients with end-stage kidney disease, offering greater independence and mobility. Holly is an investigational device and not yet approved for commercial use.
Implantable dialysis platform for continuous blood filtrationContinuous hemofiltration enabling on-the-go dialysisDiscreet lower abdominal catheter for at-home or mobile useCartridge-based membrane system for scheduled replacementProprietary membrane platform and edge computing technologyPotential applications in liver and metabolic toxin management, critical care, and long-duration spaceflights
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to NEPHRODITE, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.